National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
Stroke. 2022 Mar;53(3):1030-1036. doi: 10.1161/STROKEAHA.121.036582. Epub 2022 Jan 11.
In the present short review for the Sherman Award, Dr Yamaguchi introduces studies at the National Cerebral and Cardiovascular Center, Osaka, which included development of intravenous thrombolysis using low-dose alteplase that was officially approved in Japan, long-term dual antiplatelet therapy using cilostazol together with aspirin or clopidogrel, and others. He also discusses efforts to ensure the passage of the "Stroke and Cardiovascular Disease Control Act," the aims of which are better primary prevention, better acute treatment, rehabilitation, and secondary prevention of stroke for people living in Japan.
在本次 Sherman 奖的简短回顾中,山口博士介绍了日本国立循环器病研究中心的研究工作,包括使用低剂量重组组织型纤溶酶原激活剂进行静脉溶栓治疗的研究,该研究最终获得日本官方批准;联合使用西洛他唑、阿司匹林或氯吡格雷进行长期双联抗血小板治疗的研究等。他还讨论了为确保《脑卒中与心血管疾病控制法案》获得通过所做的努力,该法案的目标是改善日本民众的初级预防、急性治疗、康复和脑卒中二级预防。